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Abstract  
 Introduction: Recently, Growth hormone deficiency (GHD) has 
become one of the reasons of significant metabolic and psychological 
morbidity in children and adults. The aim of our study was to find out the 
impact of GH replacement therapy on lipid profile in Georgian patients with 
GHD, which was caused by surgical resection. Design: Double Blind 
placebo controlled study for 12 months and an open study for another 12 
months. Patients and Methods: 20 Georgian adults, aged 40.75±2.2 years 
(mean ± SE, range 20.5-60), with adult onset GH deficiency were enrolled in 
the study. The patients were selected from the basis of National Institute of 
Endocrinology. We set the inclusive and exclusive criteria to study these 
patients, who needed the growth hormone replacement therapy. We collected 
standardized information about central and peripheral hormones, metabolic 
activity and physical features. Results: after 12 months of GH replacement, 
there was no significant improvement of lipid profile in the GH deficient 
patients. After 24 months of the treatment, the study showed the upward 
trend of Triglycerides, Total cholesterol and HDL-CH, and a decrease of 
LDL-CH. Conclusion: The response of lipid profile to the 12 and 24 months 
of GH replacement in patients with GH deficiency was disappointing. The 
results significantly differ from the ones, provided by the European 
Endocrine societies.  Thus, longer-term studies are required, in order to 
investigate accurately the whole lipid profile among our patients for the 
following years.  
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Introduction 
 Recently, Growth hormone (GH) and its physiological role in adult 
life have received huge attention, since the GH has an important impact on 
lipid and carbohydrate metabolism.  
 Deficiency of GH in adults causes multiple symptoms: reduced lean 
body mass, increased abdominal fat, abnormal carbohydrate and lipid 
metabolism, reduced exercise capacity, and reduced bone mineral density 
(Bengsson, et al., 1997.Rosel T, et al., 1997).  
 Untreated GHD seems to be a reason of cardiovascular risk factors 
such as increased visceral adiposity; premature atherosclerosis; impaired 
cardiac performance, elevated peripheral insulin resistance, even an 
abnormal cardiac structure. (Jorgensen, et al., 1989) 
 Hypopituitarism in adults is associated with increased vascular 
mortality and morbidity. (Prabhakar et al., 2006).  
 Cross -sectional surveys have been conducted in the several centers 
of the different countries.    They have confirmed higher prevalence of the 
cardiovascular and metabolic disorders in the patients with hypopituitarism 
(including growth hormone deficiency), in comparison with the general 
population (considering the age-, sex and weight features) (Wtister et al., 
1991.de Boer et al., 1994.). 
 Above-mentioned changes can be treated by replacement treatment 
with synthetic GH therapy, in addition, most of the patients also reported a 
significant improvement in life quality (Kellner et al.,1987. Mchorney et al., 
1993. Mckenna et al., 1999. Degerblad et al., 1990).   
According to the International Endocrine associations, GH treatment 
has the beneficial impact on body fat distribution, lipid abnormalities and 
flow mediated dilation, thus it seems to reduce the risk of cardiac morbidities 
in adults with GHD. (Lanes et al., 2008. Munzer et al., 2001). The recent 
blinded, randomized, placebo-controlled trials have shown a remarkable 
decrease in low-density lipoprotein cholesterol (LDL) levels and total 
cholesterol in the GHD adults, following GH replacement treatment, 
compared to the baseline level and the same profile of placebo-treated 
subjects. (Murray, et al., 2002. Salomon, et al., 1989). In the study conducted 
by Beshyah- Henderson, the l8 months of GH replacement therapy in 
hypopituitary adults produced beneficial effects on the plasma lipid profile. 
(Beshyah, et al., 1994). 
 The benefits of GH replacement therapy are not studied appropriately 
yet; However, it is confirmed that recombinant GH is well tolerated, with a 
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low incidence of side effects and it improves most of the alterations observed 
in GH deficient adults (Johansson, et al., 1997. Reed, et al., 2003. Lucidi, et 
al., 2002) 
In our study, we report the 24 months result of GH therapy on 
lipid metabolism in the Georgian Patients with adult onset 
growth hormone deficiency.  
 
Methods 
 This prospective, double blind study was conducted at the National 
Institute of Endocrinology (Tbilisi, Georgia). The study protocol was 
approved by the ethical committee of the National Institute of 
Endocrinology, according to the declaration of Helsinki. The Inclusion 
Criteria were as follows: 
 Males and females aged 18 years or over; 
 Diagnosis of adult GHD for at least 6 months, or patients who have 
hypopituitarism resulting from surgical resection; 
 No history of exposure to any GH within the past 12 months prior to 
screening; 
 Adequate doses of replacement hormones (vasopressin, 
levothyroxine, fludrocortisone) for at least 6 months prior to screening; 
 No history of Statin therapy, within the past 12 months. 
Exclusion criteria: 
 Patients with acute or chronic conditions or diseases that could 
confound results of the study. 
 Presence of contraindications to GH treatment. 
 Patients who have participated in the clinical studies within 6 months 
of screening. 
 Patients with active malignant diseases (except the surgically 
removed basal cell carcinoma) 
  Patients with a new diagnosis of pituitary adenoma within the 15 
months of screening 
 Presence of untreated adrenal insufficiency, active acromegaly in the 
past 4 years, or active Cushing's syndrome in the past 1,5 years 
 Patients with type 1 diabetes mellitus or uncontrolled type 2 diabetes 
mellitus (glycated hemoglobin (HBA1c) of ≥8%) 
 Twenty patients (11 females and 9 males) were studied. They were 
recruited from the National Institute of Endocrinology. All the twenty 
patients had acquired the condition during their adult life, after the surgery 
on the pituitary gland, causing Hypopituitarism. (hypopituitarism is defined 
as a disorder in which the pituitary gland does not produce one or more 
hormones). 
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Study protocol  
 After baseline assessments, patients were enrolled in a randomized, 
double blind, placebo-controlled trial of either GH or placebo for the 24 
months period. 
 Patients were reviewed at 0, 6, and 12 months during the double 
blind, placebo-controlled study, (n=20), followed by an open trial of another 
12-months duration (n=10). 
 
Laboratorial Features 
 GH deficiency was defined biochemically, based on the results of the 
blood GH, IGF and IGF binding protein3tests. Levels of GH were tested 7 
times during 120 minutes. Serum GH response to insulin-induced 
hypoglycemia (blood glucose, ~2.2mmol/L) was used to define GH 
deficiency. 
 In this study, the proposed reference intervals of the standard kit for 
the above-mentioned tests were as follows:  
GH 
Time Normal reference 
0, minute 0-10 mIUml 
Stimulated Gh after 15, 30, 45, 
60, 90, 120 minutes 
> 10 mIUml 
 
 IGF-1  
Age Normal reference  
16-24 182 to 780 ng/ml 
25-39 114 to 492 ng/ml 
40-54 90 to 360 ng/ml 
>55 71 to 290 ng/ml 
 
IGFbp3  
Age Normal reference 
20-35 3.5-7.6 mcg/ml 
35-40  3.3-6.7  mcg/ml 
>40  3.3-6.7  mcg/ml 
  
   
   
   
 GH replacement Placebo 
N 10 10 
Sex F-8 M-2 F-3 M-7 
BMI (kg/m2) 28.9±2.8 27.6±3.9 
Duration of Hypopituitarism 2 yrs±3months 2yrs±5 months 
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 Plasma lipids were measured after 10 hr. overnight fasting period. 
Serum cholesterol and triglyceride levels were assayed enzymatically. High 
density lipoprotein (HDL) cholesterol was assayed after precipitation of 
other lipoproteins with dextran sulfate and magnesium. LDL cholesterol was 
calculated from Fried Wald’s formula. 
 A human growth hormone, comprised of the authentic human GH 
sequence, was given weekly by intramuscular injection. The starting weekly 
dose was 0,33 IU/kg and was later adjusted according to patients’ tolerance 
by 25% or 50% decrements, as required. The placebo consisted of freeze-
dried sterile sodium bicarbonate. 
 
Results 
Patients 
 10 Georgian patients with Hypopituitarism received Recombinant 
growth hormone for 24 months, other 10 patients (as control group) did not 
receive the medication. The patients of the both groups had adult onset 
growth hormone deficiency.   
 The mean age of the patients was 40.75±2.2 years. At baseline, all the 
patients (in treatment and control groups) had dyslipidemia. Furthermore, 
After the surgery on the pituitary gland adenoma, 90% of the patients 
suffered other symptoms, related to GHD, such as: myalgia, arthralgia, 
chronic fatigue syndrome, weight gain (6±2.4kg). We recommended all the 
patients to be physically active and to follow a healthy diet.  
 
The effects of the treatment  
 We decided to control and compare the baseline values of lipid 
profile to the levels obtained at the 12th   and the 24th months of the study. 
 Among the GH treated patients, there was an increase of mean values 
of LDL-CH, total cholesterol (CH) and triglycerides (TG), After 12 months 
of the study. Surprisingly, there was a decrease of Total CH, LDL-CH and 
TG, in the patients not receiving the GH. HD-Ch was elevated in the both 
groups.   We presume, it could be result of the healthy diet and Physical 
activity.  (Table 1) 
Table 1 GH effect on lipid profile after 12 months of the study 
 
 
 Month 0 Month 12 Month 0 Month 12 
Total cholesterol 5.44±1.1mmol/l 5.54 ±0.9mmol/l 4.96 ±1.2mmol/l 4.89±0.97mmol/l 
HDL-CH 0.8 ±0.25 mmol/l 1 ±0.33mmol/l 1.2 ±0.98mmol/l 1.25 ±1.1mmol/l 
LDL-CH 3.55 ±1.3mmol/l 3.65 ±1.5mmol/l 3.1 ±1.12mmol/l 3.0 ±1.3mmol/l 
Triglycerides 2.2 ±0.56mmol/l 2.5 ± 0.4mmol/l 1.5 ±0.9mmol/l 1.4 ±0.7mmol/l 
       Treatment group             Control group 
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 However, the Study group showed, that the total CH /HDL and 
LDL/HDL cholesterol ratios were decreased. Based on this, we conc luded, 
that the 12-months Study period was not sufficient to determine the full 
impact of GH on lipid profile. Thus, it was important to observe the data in 
open trial study, (n=10) for another 12- months period;  
 From Baseline to 24 months of treatment, there was a significant 
increase in median Total cholesterol and Triglycerides in the GH treated 
patients (Figure 1, Table 2), TG +22.73%, total CH +5.56%). However, there 
was an evident improvement regarding LDL-CH and HDL-CH values, (LDL 
-11.43%; HDL +50%). 
Fig.1 Levels of lipid profile at Baseline and after  12th month and the 24th month of the GH 
treatment (study group) 
  
Values are the mean ± SD.  
 
Table 2.Percentage change in Lipid profile in GH treatment group 
 
Indicators Median % change from the baseline 
 12 Months 24 Months 
Triglycerides +13.64% +22.73% 
Total Cholesterol +2.59% +5.56% 
HDL-CH +25% +50% 
LDL-CH +4.29% -11.43% 
 
 
 
0
1
2
3
4
5
6
TG Total Chol. HDL LDL
0 month 12 months 24 months
M
m
o
l/
L
 
European Scientific Journal September 2017 edition Vol.13, No.27 ISSN: 1857 – 7881 (Print) e - ISSN 1857- 7431 
 
25 
Discussion 
 In the present study, we examined both: the short and long-term 
effects of GH therapy on lipid metabolism in adults with GH deficiency. The 
12-months placebo controlled period was followed by an open trial, which 
lasted other 12 months. In Georgia, it was the first study on GHD and its 
effects on lipid profile in adults. GH deficiency was defined on the basis 
of stimulated GH response less than 10mU/l.  The most of the patients had 
severe GH deficiency (below 4 mU/l).  As long as, GHD seems to be one of 
the reasons of dyslipidemia, we found it important to study GH replacement 
effect on the plasma lipid metabolism. 
 Surprisingly, the results we expected were somehow different from 
the ones, we have received. In our study, it was obvious that the lipid profile 
was significantly worsened after GH treatment- total 
cholesterol, triglycerides and LDL-CH were elevated after 12 months of 
the study, it was only HDL-CH, which showed slight improvement. The 
period of another 12 months of the study was also interesting for us, since 
TG and total CH continued to elevate stably. However, LDL-CH was 
significantly decreased, as for HDL- CH, it showed the best response to GH 
treatment (+50%, after 24 months of the treatment).  
 Obviously, the high levels of total Ch and TG are important 
indicators of dyslipidemia, that is why, our study confirms, that GH 
treatment can have unsatisfactory effects on lipid profile. The reason of 
that can be an environment, the nutritional habits, lifestyle etc. 
 The results of our study are not consistent with the data obtained in 
other studies, confirming total improvement of lipid profile after GH 
replacement therapy. 
 Considering possible reasons, we still find it difficult to explain the 
deviations in the studies of other researchers. We presume it could be the 
result of the different duration of the study, GH dose or injection 
frequency, preexisting lipid profile, coexisting illnesses etc. e.g. In Beshyah-
Hendersons’ study (study duration - 18 months) GH at a dose of 0.04 IU/kg 
was injected daily; (Beshyah, et al.,1994), while in our study, that lasted 24 
months, GH was injected once weekly at a dose of 0,33 IU/kg/week.  
 However, there are couple of studies, which have shown that GH 
treatment improve the lipid profile, just partially (e.g Salomon’s study   
demonstrated a significant reduction in total cholesterol, but not in plasma 
triglycerides after 6 months of GH treatment, (Salomon et al, 1989). 
 Does the GH treatment induce the total improvement of the lipid 
profile in GHD adult patients?  The results of our study put this issue under 
doubt.  
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Conclusion 
 The present study provides a good example, that several issues 
regarding the replacement therapy in the patients with hypopituitarism must 
be checked in different countries, on several clinical bases. We find it 
important to continue our study to determine whether prolonged GH 
replacement has the beneficial effect on the lipid profile or not. 
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